Coastlands Reports 2.82M Shares, 5.98% of WHWK Common Stock
Rhea-AI Filing Summary
Coastlands-related parties report beneficial ownership of 2,819,215 shares of Whitehawk Therapeutics common stock, representing 5.98% of the outstanding shares based on 47,128,362 shares cited as of August 4, 2025. The holdings are reported across Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry. Voting and dispositive power is reported as shared for most entities, with Coastlands Capital GP LLC showing sole voting and dispositive power in one cover-sheet entry, while other reporting persons indicate shared power. The filing states the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of the issuer.
Positive
- Material ownership disclosed: Reporting persons own 2,819,215 shares, equating to 5.98% of the class, enhancing market transparency.
- Clear attribution across entities: The filing identifies the adviser, partnership, general partner and control person, clarifying ownership relationships.
- Passive intent declared: The securities are stated to be held in the ordinary course of business and not to effect control, consistent with Schedule 13G treatment.
Negative
- None.
Insights
TL;DR A single investor group holds just under 6% of WHWK, disclosed as shared ownership and presented as passive in intent.
The Schedule 13G shows a 5.98% ownership stake, large enough to trigger disclosure but below typical activist thresholds. The split of voting and dispositive power across affiliated entities suggests centralized control through the general partner structure while maintaining adviser/partnership distinctions. This is a routine, material ownership disclosure that increases investor transparency but does not by itself indicate a change in strategic direction or control.
TL;DR Reporting structure indicates coordinated ownership via adviser and GP, disclosed as not seeking control.
The filing clarifies roles: the partnership holds the shares for investors, the adviser and GP exercise reported powers, and the named individual is the control person of the related entities. The certification that the position is held in the ordinary course and not for control is typical for a Schedule 13G. Governance implications are limited absent further accumulations or coordination with other investors.
FAQ
How many Whitehawk Therapeutics (WHWK) shares do Coastlands reporting persons own?
Does the Schedule 13G indicate Coastlands intends to take control of WHWK?
Which Coastlands entities are named on the filing for WHWK?
What type of voting and dispositive power is reported for these shares?
On what share count is the 5.98% ownership percentage based?